Estamos no ar no ! Saiba mais
ícone de LMRI

Lumexa Imaging Holdings

10,78 USD
0,00
0%
No fechamento Atualizado 16 de out. 16:00 EDT
1 dia
0%
5 dias
2,08%
1 mês
-7,47%
3 meses
-3,75%
6 meses
18,98%
No acumulado do ano
-38,58%
1 ano
-41,79%
5 anos
-41,79%
10 anos
-41,79%
 

Sobre: Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography. Its products and operations are managed and reported in two operating segments: Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The professional services segment generates revenue from interpreting imaging studies conducted by other parties, mainly hospital imaging departments. The majority of revenue is generated by the Outpatient segment, which performs imaging studies and provides radiologists' interpretations of those studies.

Funcionários: 4.335

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 37,5%
Neutro 62,5%
Negativo 0%
Positivo
Zacks Investment Research
mês passado
Lumexa (LMRI) Upgraded to Buy: Here's What You Should Know
Lumexa (LMRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Lumexa (LMRI) Upgraded to Buy: Here's What You Should Know
Neutro
GlobeNewsWire
mês passado
Lumexa Imaging Announces Participation in Upcoming Investor Conferences
RALEIGH, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging Holdings, Inc. (“Lumexa Imaging”) (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, announced today that Caitlin Zulla, CEO, and Tony Martin, CFO, will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference, held in Boston, including a fireside chat at 3:00 PM ET and one-on-one meetings with Caitlin Zulla and Tony Martin on September 9, 2026.
Lumexa Imaging Announces Participation in Upcoming Investor Conferences
Positivo
Zacks Investment Research
mês passado
Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?
The consensus price target hints at a 36.9% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 36.88% Upside in Lumexa (LMRI): Can the Stock Really Move This High?
Neutro
Seeking Alpha
há 2 meses
Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript
Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript
Lumexa Imaging Holdings, Inc. (LMRI) Q2 2026 Earnings Call Transcript
Positivo
MarketBeat
há 2 meses
Lumexa Imaging Q2 Earnings Call Highlights
Lumexa Imaging NASDAQ: LMRI reported second-quarter revenue growth, higher advanced-imaging volumes and a return to profitability, while narrowing its full-year adjusted EBITDA outlook and reiterating revenue and adjusted earnings-per-share guidance.
Lumexa Imaging Q2 Earnings Call Highlights
Neutro
GlobeNewsWire
há 2 meses
Lumexa Imaging Announces Second Quarter 2026 Results
RALEIGH, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today reported results for the second quarter ended June 30, 2026, and updated its full year 2026 outlook.
Lumexa Imaging Announces Second Quarter 2026 Results
Neutro
GlobeNewsWire
há 2 meses
Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date
RALEIGH, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced it will release its second quarter 2026 financial and operational results after market close on Wednesday, August 12, 2026.
Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date
Neutro
Zacks Investment Research
há 2 meses
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Positivo
Zacks Investment Research
há 3 meses
Wall Street Analysts Think Lumexa (LMRI) Could Surge 44.08%: Read This Before Placing a Bet
The mean of analysts' price targets for Lumexa (LMRI) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Lumexa (LMRI) Could Surge 44.08%: Read This Before Placing a Bet
Positivo
Zacks Investment Research
há 3 meses
Wall Street Analysts Believe Lumexa (LMRI) Could Rally 73.25%: Here's is How to Trade
The consensus price target hints at a 73.3% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Lumexa (LMRI) Could Rally 73.25%: Here's is How to Trade
Gráficos de preços implementados com Lightweight Charts™